Zydus Pharmaceuticals Inc, the US arm of Zydus Cadila has entered into a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a business unit of Tyco Healthcare to market generic products in the US.

Under the terms of the agreement, the generic products will be developed and registered by Zydus Pharmaceuticals and manufactured by Zydus Cadila at its USFDA-approved plant in Ahmedabad, Zydus said on Wednesday.

Mallinckrodt will market and sell the products under a joint Mallinckrodt-Zypharma label, it added.

The strategic pact between the two companies is for a period of five years and would be extended further by mutual consent, it said.

Zydus has received approvals to market Atenolol and Clindamycin from the USFDA, it added.